AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00644020
Drug: mitomycin, Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
Trial: NCT04603586
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course
Trial: NCT00345761
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
Trial: NCT02798835
Drug: Adductor canal catheter
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
Trial: NCT02798835
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: May or may not be used in spinal anesthetic
Trial: NCT01451489
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
Trial: NCT00168922
Drug: Bendamustin/Ribomustin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00046995
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00046995
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03684213
Drug: Norepinephrine + Ascorbic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention is meant to globally assess the impact of oxidative stress on vasoconstrictor responses by scavenging numerous oxidative molecules.
Trial: NCT03684213
Drug: Norepinephrine + L-NAME
RxNorm normalized name: L-Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention is meant to assess the impact of endothelium-derived nitric oxide on vasoconstrictor responses by inhibiting production of this source of nitric oxide.
Trial: NCT03684213
Drug: Norepinephrine + L-NAME + Ascorbic Acid
RxNorm normalized name: L-Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention is meant to assess the combined impact of scavenging oxidative stress and inhibiting endothelium-derived nitric oxide on vasoconstrictor responses.
Trial: NCT00636064
Drug: Parecoxib Sodium/Valdecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Trial: NCT00636064
Drug: Placebo/Valdecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Trial: NCT03951207
Drug: Rosuampin 10/5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
Trial: NCT03951207
Drug: Rosuampin 20/5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuampin 20/5mg qd for 8 weeks
Trial: NCT03399370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Trial: NCT01839578
Drug: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~* 4% trisodium citrate solution~* Calcium chloride solution (100 mmol/L)~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~* Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~* Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~* Blood flow adapted to the acid-base status
Trial: NCT01839578
Drug: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)
RxNorm normalized name: ANTICOAGULANT CPDA-1 THE CLX SYSTEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~* Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~* Standard dialysate for CRRT : Prismasol® K2 solution~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of
Trial: NCT03907098
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice
Trial: NCT02929485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200mg) administered at study visit
Trial: NCT01755949
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
Trial: NCT00539994
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg BID placebo 5 days
Trial: NCT00356681
Drug: AMG 706 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded placebo
Trial: NCT03738111
Drug: TG02 Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG02 citrate capsules
Trial: NCT02867566
Drug: IBI301 plus CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
Trial: NCT00584883
Drug: ABT 510
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
Trial: NCT01245452
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
Trial: NCT03832816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vapor (distilled water)
Trial: NCT03832816
Drug: Vaporized THC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute exposure to vaporized THC
Trial: NCT03832816
Drug: Vaporized CBD alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute exposure to vaporized CBD
Trial: NCT03832816
Drug: Vaporized CBD with THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute exposure to vaporized CBD with THC
Trial: NCT00264199
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same rate of infusion as GLP-1
Trial: NCT00239733
Drug: Anti-D
RxNorm normalized name: D-Gam Anti-D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute infusion administered in an outpatient setting
Trial: NCT00415285
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00415285
Drug: Docetaxel/Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01736891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, qd
Trial: NCT00841633
Drug: Induced hypertension with norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
Trial: NCT00114699
Drug: CCR5mAb004
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02708095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02491723
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with bronchiectasis treated with Azithromycin for three to five days.
Trial: NCT00760955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
Trial: NCT03259555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally daily for 3 weeks.
Trial: NCT02021669
Drug: Omega-3 supplement
RxNorm normalized name: Systane Vitamin Omega-3 Supplement Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks
Trial: NCT02021669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
Trial: NCT04090411
Drug: Induction- PF-06480605 150 mg SC Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06480605
Trial: NCT04090411
Drug: Induction- PF-06480605 450 mg SC Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06480605
Trial: NCT04090411
Drug: Chronic- PF-06480605 150 mg SC Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06480605
Trial: NCT00209859
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01242592
Drug: Anti-Tuberculosis Treatment
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03213249
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
Trial: NCT01112397
Drug: AZD1480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous daily oral capsule
Trial: NCT01943799
Drug: OAV Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
Trial: NCT00286585
Drug: Inhalational anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane, dosage according to the physician in charge
Trial: NCT04151407
Drug: Drug 601
RxNorm normalized name: ethanol 0.601 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
Trial: NCT04437485
Drug: Antidepressant Medications
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We first considered all FDA-approved antidepressants and excluded those with weight gain effects (tricyclics, paroxetine, mirtazapine) and those rarely used in primary care (MAOIs). Then, we used existing evidence to inform the structure. We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss. We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight. Our team will make recommendations to the patient's PCP, who will write prescriptions. Our team and the PCP will then collaboratively manage pharmacotherapy.
Trial: NCT03196804
Drug: LC28-0126
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC28-0126
Trial: NCT03196804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02020616
Drug: LY3053102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05487521
Drug: Methylprednisolone and or prednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language
Trial: NCT04026321
Drug: SQ001 125mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
Trial: NCT04026321
Drug: SQ001 250mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute
Trial: NCT04026321
Drug: SQ001 500mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
Trial: NCT04026321
Drug: SQ001 625mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
Trial: NCT04026321
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
Trial: NCT02867267
Drug: Thymosin alpha 1
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
Trial: NCT02020616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04282252
Drug: I.V. SOLUTIONS
RxNorm normalized name: I.V. SOLUTIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All i.v. fluids used in an Intensive Care Unit.
Trial: NCT01165983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg tablet, taken orally for 12 weeks daily
Trial: NCT00974753
Drug: Ketorolac 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
Trial: NCT01071993
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
Trial: NCT00305695
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01117181
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
Trial: NCT00920244
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
Trial: NCT02177318
Drug: Spiriva (tiotropium bromide) inhalation capsules
RxNorm normalized name: Spiriva Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
Trial: NCT05112354
Drug: systemic and intratympanic injection of steoid
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2-Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator.
Trial: NCT03579940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01487135
Drug: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
Trial: NCT01487135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
Trial: NCT00303836
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01132807
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00786006
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
Trial: NCT01132807
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01132807
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo radiation therapy
Trial: NCT03202407
Drug: Calcium acetate and sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
Trial: NCT03624166
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive 3 ml of isotonic saline after spinal anesthesia
Trial: NCT01751984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 8 weeks
Trial: NCT02430090
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: this used in intratechal area and for spinal anesthesia in ceserean section
Trial: NCT02430090
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: this used in intratechal area and for spinal anesthesia in ceserean section
Trial: NCT02911870
Drug: SNAC
RxNorm normalized name: Glucerna Snack Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02911870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03512171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oral dose of placebo to estimate D2 receptor levels at baseline with PET imaging (necessary to calculate dopamine release in the amphetamine condition).